

Spark Therapeutics, Inc.  
Form SC14D9C  
February 25, 2019

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 14D-9**

**SOLICITATION/RECOMMENDATION STATEMENT**

**UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934**

**Spark Therapeutics, Inc.**

**(Name of Subject Company)**

**Spark Therapeutics, Inc.**

**(Name of Persons Filing Statement)**

**Common Stock, par value \$0.001 per share**

**(Title of Class of Securities)**

**84652J103**

**(CUSIP Number of Class of Securities)**

**Jeffrey D. Marrazzo**

**Chief Executive Officer**

**3737 Market Street**

**Philadelphia, PA 19104**

**(Name, Address and Telephone Number, including area code, of Agent For Service)**

*With copies to:*

**Stuart M. Cable, Esq.**

**Lisa R. Haddad, Esq.**

**Blake Liggio, Esq.**

**Goodwin Procter LLP**

**100 Northern Avenue**

**Boston, MA 02210**

**(617) 570-1000**

**(Name, address, and telephone numbers of person authorized to receive notices and communications  
on behalf of the persons filing statement)**

Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

The information set forth under Items 1.01, 5.03, 7.01 and 9.01 of the Current Report on Form 8-K filed by Spark Therapeutics, Inc. on February 25, 2019 (including all exhibits attached thereto) is incorporated herein by reference.